TG Therapeutics (TGTX) Tops Q3 EPS by 6c

TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.28), $0.06 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $38.1 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Morgan Stanley Downgrades Infineon Technologies (IFX:GY) (IFNNY) to Equalweight
• Barclays Downgrades Ipsen SA (IPN:FP) (IPSEF) to Underweight